OptimizeRx (OPRX) Cash & Equivalents (2016 - 2026)
OptimizeRx's Cash & Equivalents history spans 16 years, with the latest figure at $23.4 million for Q4 2025.
- On a quarterly basis, Cash & Equivalents rose 74.63% to $23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.4 million, a 74.63% increase, with the full-year FY2025 number at $23.4 million, up 74.63% from a year prior.
- Cash & Equivalents hit $23.4 million in Q4 2025 for OptimizeRx, up from $19.5 million in the prior quarter.
- Over the last five years, Cash & Equivalents for OPRX hit a ceiling of $89.0 million in Q1 2022 and a floor of $9.8 million in Q2 2023.
- Historically, Cash & Equivalents has averaged $37.9 million across 5 years, with a median of $17.4 million in 2022.
- Biggest five-year swings in Cash & Equivalents: soared 705.21% in 2021 and later plummeted 88.78% in 2023.
- Tracing OPRX's Cash & Equivalents over 5 years: stood at $84.7 million in 2021, then tumbled by 78.5% to $18.2 million in 2022, then decreased by 23.93% to $13.9 million in 2023, then dropped by 3.41% to $13.4 million in 2024, then soared by 74.63% to $23.4 million in 2025.
- Business Quant data shows Cash & Equivalents for OPRX at $23.4 million in Q4 2025, $19.5 million in Q3 2025, and $16.6 million in Q2 2025.